Volume 3, Issue 1 (3-2024)                   RHMS 2024, 3(1): 1-9 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezazadeh Kermani Y, Hosseinzadeh M, Rezaeian Aval A, Arasteh A, Saberi Noghabi E, Ahmadi Chenari H, et al . Developing a Care Guideline for Patients with Duchenne Myotonic Dystrophy and Their Families: a Literature Review. RHMS 2024; 3 (1) :1-9
URL: http://jrhms.thums.ac.ir/article-1-99-en.html
Developing a Care Guideline for Patients with Duchenne Myotonic Dystrophy and Their Families: a Literature Review
Yalda Rezazadeh Kermani1 , Mohaddeseh Hosseinzadeh2 , Atefeh Rezaeian Aval3 , Azadeh Arasteh4 , Elham Saberi Noghabi5 , Hadi Ahmadi Chenari2 , Hassan Eslami Aliabad6 , Ali Khosravy Bonjar *7
1- Islamic Azad University of Kerman Branch, Kerman, Iran
2- Department of Nursing, Ferdows Faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran & Hazrat Rasoul Hospital of Ferdows, Birjand University of Medical Sciences, Birjand
3- Department of Nursing, Ferdows Branch, Islamic Azad University, Ferdows, Iran
4- Counseling in Midwifery, Torbat Jam faculty of medical sciences, Torbat Jam, Iran
5- Department of Community Health Nursing and Nursing Management, School of Nursing, Social Development and Health Promotion Research Center, Gonabad University, Gonabad, Iran
6- Department of Nursing, Ferdows Faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran
7- Department of Nursing, Faculty of allied medical science, Zabol University of medical science, Zabol, Iran , Khosravia891@gmail.com
Abstract:   (140 Views)
Duchenne Muscular Dystrophy (DMD) is a life-threatening inherited disease in children, for which no effective therapies currently exist. Family members undergo emotional and socioeconomic strain while providing care for a child with Duchenne dystrophy. Therefore, there is an urgent need for patient- and family-centered care programs. The purpose of this study was to develop a comprehensive guideline to support families caring for individuals with DMD. A five-step review was undertaken as follows: defining the review question, setting the review objectives, searching databases to identify relevant studies, selecting studies according to set criteria, and extracting and analyzing data. In the third stage, a review of the existing literature was done using PubMed, CINAHL, Science Direct, Ovid, Embase, Pro Quest, Web of science and Google Scholar between 1991 and 2024. Researchers used the MESH keywords muscular dystrophy, Duchenne, comprehensive health care, and caregiver separately or in combination. The findings identified disease-related complications and corresponding care interventions that can be undertaken by family members. These interventions included pain management, promotion of muscle strength, assistance with activities of daily living, considerations related to medication use, cardiac management, respiratory care, gastrointestinal management (including nutrition and swallowing), psychosocial support, and management of endocrine and metabolic functions. Since Duchenne dystrophy is chronic, self-care and the role of the family in these patients are very important. Family contributes significantly to preventing physical, psychological, and social problems in these patients and improves their quality of life.
Keywords: Muscular dystrophy, Duchenne, Comprehensive health care, Caregiver
Full-Text [PDF 1051 kb]   (160 Downloads)    
Subject: General
Received: 2025/10/19 | Accepted: 2025/12/27 | Published: 2026/01/10
References
1. Chung, J.; Smith, A.L.; Hughes, S.C.; Niizawa, G.; Abdel-Hamid, H.Z.; Naylor, E.W.; Hughes, T.; Clemens, P.R. 20-year Follow-up of newborn screening for patients with muscular dystrophy.Muscle Nerve 2015, doi:10.1002/mus.24880. [DOI:10.1002/mus.24880]
2. NINDS Muscular Dystrophy Information Page. National Institute of Neurological Disorders and Stroke.2016; http://www.ninds.nih.gov/disorders/md/md.htm.
3. Nozoe KT, Akamine RT, Mazzotti DR, et al. Phenotypic contrasts of Duchenne Muscular Dystrophy in women: Two case reports. Sleep Science. 2016;9(3):129-133. [DOI:10.1016/j.slsci.2016.07.004]
4. Ferlini, A.; Neri, M.; Gualandi, F. The medical genetics of dystrophinopathies: Molecular genetic diagnosis and its impact on clinical practice. Neuromuscul. Disord. 2013, 23, 4-14. [DOI:10.1016/j.nmd.2012.09.002]
5. Findlay, AR.; Wein, N.; Kaminoh, Y.; Taylor, L.E.; Dunn, D.M.; Mendell, J.R.; King, W.M.;
6. Pestronk, A.; Florence, J.M.; Mathews, K.D.; et al. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45. Ann. Neurol. 2015, 77, 668-674. [DOI:10.1002/ana.24365]
7. Ahmadi Chenari H, Zakerimoghadam M, Baumann SL. Nursing in Iran: Issues and Challenges. Nurs Sci Q. 2020;33(3):264-267. doi:10.1177/0894318420920603. [DOI:10.1177/0894318420920603]
8. Pane, M.; Scalise, R.; Berardinelli, A.; D'Angelo, G.; Ricotti, V.; Alfieri, P.; Moroni, I.; Hartley, L.;Pera, M.C.; Baranello, G.; et al. Early neurodevelopmental assessment in Duchenne musculardystrophy. Neuromuscul. Disord. 2013, 23, 451-455. [DOI:10.1016/j.nmd.2013.02.012]
9. Wu, B.; Cloer, C.; Lu, P.; Milazi, S.; Shaban, M.; Shah, S.N.; Marston-Poe, L.; Moulton,H.M.;
10. Lu, Q.L. Exon skipping restores dystrophin expression, but fails to prevent disease progression inlater stage dystrophic dko mice. Gene Ther. 2014, 21, 785-793. [DOI:10.1038/gt.2014.53]
11. Anderson M, Elliott EJ, Zurynski Y. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. OJRD. 2013;28:22-22 [DOI:10.1186/1750-1172-8-22]
12. American Academy of Pediatrics, Committee on Hospital Care. Family-Centered Care and the Pediatrician's Role. Pediatrics. Sep 1; 2003 112(3):691-696. 2003. [PubMed: 12949306] [DOI:10.1542/peds.112.3.691]
13. Nayeri ND, Esmaeili M, Farsi Z, Chenari HA. Taking care experiences of improved comatose patients with traumatic brain injury and their families. J Family Med Prim Care. 2020;9(9):4815-4820. Published 2020 Sep 30. doi:10.4103/jfmpc.jfmpc_878_20. [DOI:10.4103/jfmpc.jfmpc_878_20]
14. Quinlivan R, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy
15. its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72-9 [DOI:10.1016/j.nmd.2004.09.009]
16. Shumyatcher Y, Shah TA, Noritz GA, et al. Symptomatic nephrolithiasis in prolonged survivors of Duchenne muscular dystrophy. Neuromuscul Disord 2008;18:561-4 [DOI:10.1016/j.nmd.2008.05.001]
17. Dickerson DM, Mariano ER, Szokol JW, Harned M, Clark RM, Mueller JT, Shilling AM, Udoji MA, Mukkamala SB, Doan L, Wyatt KEK, Schwalb JM, Elkassabany NM, Eloy JD, Beck SL, Wiechmann L, Chiao F, Halle SG, Krishnan DG, Cramer JD, Ali Sakr Esa W, Muse IO, Baratta J, Rosenquist R, Gulur P, Shah S, Kohan L, Robles J, Schwenk ES, Allen BFS, Yang S, Hadeed JG, Schwartz G, Englesbe MJ, Sprintz M, Urish KL, Walton A, Keith L, Buvanendran A. Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder. Reg Anesth Pain Med. 2023 Apr 25:rapm-2023-104435. [DOI:10.1136/rapm-2023-104435]
18. Dickerson DM, Mariano ER, Schwenk ES. Multiorganizational consensus on principles for perioperative pain management for patients with chronic pain, opioid tolerance, and substance use disorder: an infographic. Reg Anesth Pain Med. 2023 May 26:rapm-2022-103896. doi: 10.1136/rapm-2022-103896. [DOI:10.1136/rapm-2022-103896]
19. Salmaninejad A, Jafari Abarghan Y, Bozorg Qomi S, Bayat H, Yousefi M, Azhdari S, Talebi S, Mojarrad M. Common therapeutic advances for Duchenne muscular dystrophy (DMD). Int J Neurosci. 2021 Apr;131(4):370-389. [DOI:10.1080/00207454.2020.1740218]
20. Ling C, Dai Y, Fang L, Yao F, Liu Z, Qiu Z, Cui L, Xia F, Zhao C, Zhang S, Wang K, Zhang X. Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies. Hum Mutat. 2020 Mar;41(3):668-677. [DOI:10.1002/humu.23953]
21. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018 May;17(5):445-455. [DOI:10.1016/S1474-4422(18)30026-7]
22. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000; 20: 71-74. [DOI:10.1097/01241398-200001000-00016]
23. Manzur A Y, Muntoni F.Diagnosis and new treatments in muscular Dystrophies.J Neurol Neurosurg Psychiatry 2009;80:706-714 [DOI:10.1136/jnnp.2008.158329]
24. Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet (London, England) 2015; 385: 1748-1757. [DOI:10.1016/S0140-6736(15)60025-3]
25. Shakerian B, Mohammad R, Saeid D, Haghi M, Ardakani MF, Chenari HA, Baumann SL. Improving Physical Fitness and Health of Office Workers in Iran. Nurs Sci Q. 2023 Apr;36(2):186-193. doi: 10.1177/08943184221150260. PMID: 36994969. [DOI:10.1177/08943184221150260]
26. Aran A, Abazari F, Farokhzadian J, Azizzadeh Forouzi M. Comparing the perception of family-centered care from the perspectives of nursing staff and mothers of hospitalized children in children's wards. Hayat. 2018;24(1):48-58.
27. Mayer OH, Finkel RS, Rummey C, Benton MJ, Glanzman AM, Flickinger J, Lindström BM,
28. Meier T. Characterization of pulmonary function in Duchenne Muscular Dystrophy.
29. Pediatric Pulmonology 2015; 50: 487-494. [DOI:10.1002/ppul.23172]
30. Brumbaugh D, Watne L, Gottrand F, Gulyas A, Kaul A, Larson J, Tomezsko J. Nutritional and Gastrointestinal Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018 Oct;142(Suppl 2):S53-S61. [DOI:10.1542/peds.2018-0333G]
31. Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional Challenges in Duchenne Muscular Dystrophy. Nutrients. 2017 Jun 10;9(6):594. doi: 10.3390/nu9060594. [DOI:10.3390/nu9060594]
32. Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy. Nutr Clin Pract. 2015 Aug;30(4):511-21. [DOI:10.1177/0884533615586202]
33. Messina S, Vita GL. Clinical management of Duchenne muscular dystrophy: the state of the art. Neurol Sci. 2018 Nov;39(11):1837-1845. [DOI:10.1007/s10072-018-3555-3]
34. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan;9(1):77-93. [DOI:10.1016/S1474-4422(09)70271-6]
35. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010 Feb;9(2):177-89. [DOI:10.1016/S1474-4422(09)70272-8]
36. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251-267. [DOI:10.1016/S1474-4422(18)30024-3]
37. Topaloglu H. Duchenne muscular dystophy: A short review and treatment update. Iran J Child Neurol. 2021 Spring;15(2):9-15. doi: 10.22037/ijcn.v16i1.33282. Epub 2021 Mar 1.
38. Andrews JG, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther. 2018 Mar 15;9:53-63. [DOI:10.2147/AHMT.S125739]
39. Cripe LH, Tobias JD. Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy. Paediatr Anaesth. 2013 Sep;23(9):777-84. doi: 10.1111/pan.12229. Epub 2013 Jul 19. [DOI:10.1111/pan.12229]
40. Bobo JK, Kenneson A, Kolor K, Brown MA. Adherence to american academy of pediatrics recommendations for cardiac care among female carriers of duchenne and becker muscular dystrophy. Pediatrics. 2009 Mar;123(3):e471-5. doi: 10.1542/peds.2008-2643. [DOI:10.1542/peds.2008-2643]
41. Helderman-van den Enden AT, van den Bergen JC, Breuning MH, Verschuuren JJ, Tibben A, Bakker E, Ginjaar HB. Duchenne/Becker muscular dystrophy in the family: have potential carriers been tested at a molecular level? Clin Genet. 2011 Mar;79(3):236-42. doi: 10.1111/j.1399-0004.2010.01579.x. Epub 2010 Nov 11. [DOI:10.1111/j.1399-0004.2010.01579.x]
42. Hoogerwaard EM, Ginjaar IB, Bakker E, de Visser M. Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy. Neurology. 2005 Dec 27;65(12):1984-6. [DOI:10.1212/01.wnl.0000188909.89849.59]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Journal of Research in Health and Medical Sciences

Designed & Developed by : Yektaweb